4 profile kliniczne pacjentów, u których warto stosować aripiprazol Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2016
Słowa kluczowe:
aripiprazol, schizofrenia, choroba afektywna dwubiegunowa
##plugins.themes.bootstrap3.article.main##
Abstrakt
Praca przedstawia charakterystyki czterech pacjentów z rozpoznaniem schizofrenii lub choroby dwubiegunowej leczonych aripiprazolem. Omówiono objawy i problemy występujące u tych osób w kontekście profilu klinicznego działania aripiprazolu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Murawiec , S. (2016). 4 profile kliniczne pacjentów, u których warto stosować aripiprazol. Medycyna Faktów , 9(2(31), 122-125. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2247
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Bhattacharjee J., El-Sayeh H.G.: Aripiprazole versus typicals for schizophrenia. Cochrane Database Syst. Rev. 2008; (1): CD006617 [doi: 10.1002/14651858.CD006617.pub2].
2. Leucht S., Corves C., Arbter D. et al.: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657): 31-41.
3. Khanna P., Komossa K., Rummel-Kluge C. et al.: Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2013; 2: CD006569 [doi: 10.1002/14651858.CD006569.pub4].
4. Brown R., Taylor M.J., Geddes J.: Aripiprazole alone or in combination for acute mania. Cochrane Database Syst. Rev. 2013; 12: CD005000 [doi: 10.1002/14651858.CD005000.pub2].
5. Wang L.J., Ree S.C., Huang Y.S. et al.: Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013; 40: 260-266.
6. Keltner N.L.; Johnson V.: Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? Perspect. Psychiatr. Care 2002; 38: 157-159.
7. Mailman R.B., Murthy V.: Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr. Pharm. Des. 2010; 16(5): 488-501.
8. McQuade R.D., Burris K.D., Jordan S. et al.: Aripiprazole: a dopamine-serotonin system stabilizer. Int. J. Neuropsychopharmacol. 2002; (supl. 5): S176.
9. Bandelow B., Meier A.: Aripiprazole, a “dopamine-serotonin system stabilizer” in the treatment of psychosis. German J. Psychiatry 2003; 6: 9-16.
10. Lacasse J.R., Leo J.: Questionable Advertising of Psychotropic Medications and Disease Mongering. PLoS Med. 2006; 3(7): e321.
2. Leucht S., Corves C., Arbter D. et al.: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657): 31-41.
3. Khanna P., Komossa K., Rummel-Kluge C. et al.: Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2013; 2: CD006569 [doi: 10.1002/14651858.CD006569.pub4].
4. Brown R., Taylor M.J., Geddes J.: Aripiprazole alone or in combination for acute mania. Cochrane Database Syst. Rev. 2013; 12: CD005000 [doi: 10.1002/14651858.CD005000.pub2].
5. Wang L.J., Ree S.C., Huang Y.S. et al.: Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013; 40: 260-266.
6. Keltner N.L.; Johnson V.: Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? Perspect. Psychiatr. Care 2002; 38: 157-159.
7. Mailman R.B., Murthy V.: Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr. Pharm. Des. 2010; 16(5): 488-501.
8. McQuade R.D., Burris K.D., Jordan S. et al.: Aripiprazole: a dopamine-serotonin system stabilizer. Int. J. Neuropsychopharmacol. 2002; (supl. 5): S176.
9. Bandelow B., Meier A.: Aripiprazole, a “dopamine-serotonin system stabilizer” in the treatment of psychosis. German J. Psychiatry 2003; 6: 9-16.
10. Lacasse J.R., Leo J.: Questionable Advertising of Psychotropic Medications and Disease Mongering. PLoS Med. 2006; 3(7): e321.